Asceneuron SA today announces the publication of peer-reviewed data in the journal ACS Chemical Neuroscience regarding ASN90, an O–GlcNAcase (OGA) inhibitor, and one of its leading candidates in clinical development for treating neurodegenerative proteinopathies. Neurodegenerative proteinopathies such as Alzheimer’s and Parkinson’s disease are characterized by the intracellular formation in the brain of insoluble and toxic…

eTurboNews izindatshana ezababhalisi kuphela. Ukubhalisa kuyinto MAHHALA.
Ababhalisile bangena lapha Chofoza lapha ukuze ubhalise MAHHALA

LOKHO ONGAKUTHATHE KULESI SIHLOKO:

I-Asceneuron SA namuhla imemezela ukushicilelwa kwedatha ebuyekezwe kontanga kujenali i-ACS Chemical Neuroscience ephathelene ne-ASN90, i-O-GlcNAcase (OGA) inhibitor, kanye nelinye lamakhandidethi ayo ahamba phambili ekuthuthukisweni komtholampilo ekwelapheni i-neurodegenerative proteinopathies.
Neurodegenerative proteinopathies such as Alzheimer’s and Parkinson’s disease are characterized by the intracellular formation in the brain of insoluble and toxic….
eTurboNews izindatshana ezababhalisi kuphela.